Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.
reported today inWall Street Journal
AND don't forget another increase in dividend to be announced on or about December 15. I expect minimum of 10% increase to $8.50+ per year.
$AMGN gives up in BCMA race
Pavurutamab (AMG 701)
Clinical development of pavurutamab an anti-B-cell maturation antigen (BCMA) HLE BiTE molecule being investigated for the treatment of multiple myeloma, has been discontinued for strategic reasons.
Loncar:
Going to be nearly impossible for bi-specifics to compete with CAR-T efficacy in BCMA. Hard to see where they fit in.
Rennert:
also hard to see how other CAR-BCMA programs compete once JNJ gets the wheels turning on cilta-cel
Thoughts peter?
Now but it just doesn't happen... sadly there always seem to be an excuse as to why. Since I bought in at $68 in 2001 and based on that price and what the dividend is now that's about a 12% return on original investment. However, they still should be trading at a 6 to 8x from where I bought it. Oh well maybe one day they will break to the upside "when someone bigger acquires them"...
Notable that $AMGN is demonstrating a new level of confidence in $ARWR TRiM
Trade mark sign
by their manner of promoting progress with Lipoprotein(a) w/ AMG-890 formerly Arrowhead’s ARO-LPA https://amgenscience.com/features/10-things-to-know-about-lipoproteina/
Seems this blockbuster drug is moving quickly enough to merit this Amgen PR.
https://www.amgenscience.com/features/10-things-to-know-about-lipoproteina/